–
Leveraging the Company’s proprietary S1S3 bicistronic expression platform, M041 is co-expressed human NAGLU and S1S3, resulting in NAGLU
M6P –
–
With increased efficiency to phosphorylate lysosomal enzymes, M041 is a potential novel recombinant enzyme therapy for Sanfilippo B syndrome –
ST. LOUIS, MO, USA I July 28, 2021 IM6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced pre-clinical proof-of-concept data on M041 in a poster presentation by Patricia Dickson, M.D., Centennial Professor of Pediatrics and Chief, Division of Genetics and Genomic Medicine, Washington University of St. Louis, titled “
New Study on Antibody Response Shows We Should Hit the Brakes on Push for COVID Vaccine Boosters
townhall.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from townhall.com Daily Mail and Mail on Sunday newspapers.
Protection from Pfizer, Moderna COVID-19 vaccines may last for years: study
koreatimes.co.kr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreatimes.co.kr Daily Mail and Mail on Sunday newspapers.
4 Big Problems With The Above The Law Law School Rankings
abovethelaw.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from abovethelaw.com Daily Mail and Mail on Sunday newspapers.
A registered nurse draws a dose from a vial of the Johnson & Johnson COVID-19 vaccine. (Michael Ciaglo/Getty Images)
A new study that focused on the immune response to COVID-19 in patients who contracted mild cases found that antibody production lasts up to a year and may last a lifetime.
Vaccines heighten the antibody response and are crucial in protecting those who developed asymptomatic COVID-19 or never contracted the virus at all, the study finds.
Host Tonya Mosley speaks with
Dr. Ali Ellebedy, senior author on the study and professor of pathology and immunology at the Washington University of St. Louis, about his findings.